Brenus Pharma
Develops an off-the-shelf in vivo immunotherapy platform for solid tumors
€11MSeries A
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops an off-the-shelf in vivo immunotherapy platform for solid tumors
Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke
Develops silicon qubits for dense integration and compatibility with industrial fabrication standards
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Provides AI-driven decision intelligence platform for boards and senior executives
Provides medical device solutions for women living with polycystic ovary syndrome (PCOS)
Develops functional whey protein ingredients through precision fermentation for food and nutrition manufacturers
Provides a non-human identity security platform to detect and remediate leaked secrets in code
Builds AI data centers and infrastructure for enterprises
Develops small-molecule therapies for targeted protein degradation at the point of synthesis